| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.
|
Clin Infect Dis
|
2001
|
12.73
|
|
2
|
Comparison of caspofungin and amphotericin B for invasive candidiasis.
|
N Engl J Med
|
2002
|
9.21
|
|
3
|
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
|
J Clin Microbiol
|
1998
|
7.01
|
|
4
|
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.
|
Antimicrob Agents Chemother
|
1994
|
6.45
|
|
5
|
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
|
Antimicrob Agents Chemother
|
1997
|
5.76
|
|
6
|
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.
|
Antimicrob Agents Chemother
|
1997
|
4.87
|
|
7
|
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.
|
Antimicrob Agents Chemother
|
1997
|
4.14
|
|
8
|
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.
|
Clin Infect Dis
|
2000
|
3.70
|
|
9
|
In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.
|
Antimicrob Agents Chemother
|
2001
|
3.28
|
|
10
|
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.
|
Antimicrob Agents Chemother
|
1997
|
3.17
|
|
11
|
Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies.
|
Infect Immun
|
1996
|
3.08
|
|
12
|
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
|
Antimicrob Agents Chemother
|
1997
|
3.02
|
|
13
|
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.
|
Diagn Microbiol Infect Dis
|
1998
|
2.96
|
|
14
|
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.
|
Antimicrob Agents Chemother
|
2002
|
2.76
|
|
15
|
In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.
|
Antimicrob Agents Chemother
|
1997
|
2.76
|
|
16
|
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).
|
Antimicrob Agents Chemother
|
1997
|
2.73
|
|
17
|
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
|
Antimicrob Agents Chemother
|
2002
|
2.68
|
|
18
|
The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.
|
Antimicrob Agents Chemother
|
2002
|
2.60
|
|
19
|
Antibiotics that inhibit fungal cell wall development.
|
Annu Rev Microbiol
|
1994
|
2.58
|
|
20
|
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.
|
Antimicrob Agents Chemother
|
2000
|
2.51
|
|
21
|
In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions.
|
J Med Vet Mycol
|
1997
|
2.50
|
|
22
|
A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase.
|
J Bacteriol
|
1994
|
2.33
|
|
23
|
A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.
|
Clin Infect Dis
|
2001
|
2.32
|
|
24
|
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
|
J Clin Microbiol
|
1999
|
2.10
|
|
25
|
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
|
Diagn Microbiol Infect Dis
|
1998
|
2.04
|
|
26
|
Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.
|
Antimicrob Agents Chemother
|
2002
|
2.00
|
|
27
|
Treatment of murine disseminated candidiasis with L-743,872.
|
Antimicrob Agents Chemother
|
1997
|
1.87
|
|
28
|
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872.
|
Antimicrob Agents Chemother
|
1997
|
1.83
|
|
29
|
Caspofungin: an echinocandin antifungal agent.
|
Clin Ther
|
2002
|
1.71
|
|
30
|
Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.
|
Antimicrob Agents Chemother
|
2000
|
1.66
|
|
31
|
In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species.
|
Eur J Clin Microbiol Infect Dis
|
1999
|
1.62
|
|
32
|
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.
|
Am J Med
|
2002
|
1.61
|
|
33
|
Caspofungin.
|
Drugs
|
2001
|
1.45
|
|
34
|
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action.
|
J Antimicrob Chemother
|
1997
|
1.37
|
|
35
|
Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine.
|
Drug Metab Dispos
|
2000
|
1.18
|
|
36
|
Treatment of histoplasmosis with MK-991 (L-743,872).
|
Antimicrob Agents Chemother
|
1998
|
1.16
|
|
37
|
Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii.
|
Antimicrob Agents Chemother
|
1998
|
1.15
|
|
38
|
Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae.
|
Antimicrob Agents Chemother
|
2002
|
1.14
|
|
39
|
Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model.
|
Antimicrob Agents Chemother
|
2000
|
1.10
|
|
40
|
Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
|
Eur J Clin Microbiol Infect Dis
|
2010
|
0.82
|
|
41
|
Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32:320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32:321).
|
Clin Infect Dis
|
2001
|
0.75
|